z-logo
open-access-imgOpen Access
Use of etanercept to treat toxic epidermal necrolysis in a human immunodeficiency virus-positive patient
Author(s) -
YungYi Lee,
JuiHung Ko,
ChiaHung Wei,
WenHung Chung
Publication year - 2012
Publication title -
dermatologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.604
H-Index - 17
eISSN - 2223-330X
pISSN - 1027-8117
DOI - 10.1016/j.dsi.2012.06.005
Subject(s) - toxic epidermal necrolysis , medicine , etanercept , mucocutaneous zone , dermatology , human immunodeficiency virus (hiv) , adverse effect , skin biopsy , biopsy , immunology , pathology , tumor necrosis factor alpha , disease
Toxic epidermal necrolysis (TEN) is an uncommon and severe cutaneous adverse drug reaction that causes disseminated necrosis of epidermal cells and mucocutaneous detachment. Here, we report the case of a 32-year-old man with human immunodeficiency virus infection who presented with generalized violaceous macules and blister formation 4 days after the administration of mefenamic acid and amoxicillin for a dental procedure. Additional symptoms included oral ulcers and conjunctivitis. Results of skin biopsy were compatible with Stevens–Johnson syndrome (SJS). SJS progressed to TEN within 2 days. Etanercept treatment showed a dramatic improvement in the symptoms of mucocutaneous lesions. To our knowledge, this is the first report on the treatment of TEN using etanercept in a human immunodeficiency virus-positive patient

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom